The reiteration of a Buy rating and maintenance of an $80 price target by a reputable analyst firm like HC Wainwright & Co. suggests a strong conviction in Celldex Therapeutics' potential for growth and success. This positive analyst outlook can influence investor sentiment and potentially lead to a short-term increase in stock price.